Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Heatmap
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CVKD
#4818
Cadrenal Therapeutics, Inc. Common Stock
4.8
1
USD
+0.42%
Setor:
Cuidados de saúde
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
+0.42%
Mudança mensal
-35.26%
Mudança em 6 meses
-12.86%
Mudança anual
-12.86%
Fechamento anterior
4.7
9
Abrir
4.8
1
Bid
Ask
Mínimo
4.8
1
High
4.8
1
Volume
2
Mercados
Ações
Cuidados de saúde
CVKD
Abrir gráfico completo
Financials
Visão geral
Relatórios
Estatísticas
Trimestral
Ano
Valor
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
1.88 M
1.97 M
2.05 M
2.08 M
2.51 M
—
Valuation ratios
Enterprise value
17.24 M
27.34 M
19.66 M
24.85 M
12.99 M
84.84 M
Price to earnings ratio
-1.66
-1.9
-1.36
-1.72
-1.02
-6
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-2.4
-2.38
-1.6
-2.07
-1.07
-7.12
Price to book ratio
2.38
1.09
0.82
1.07
4.94
7.91
Enterprise value to EBITDA ratio
-1.57
—
—
—
—
—
Profitability ratios
Return on assets %
-0.41
-0.48
-0.61
-0.66
-0.7
-2.46
Return on equity %
-0.56
-0.63
-0.85
-0.98
-1.11
-3.57
Return on invested capital %
-173.12 K
—
—
—
-44.46 K
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.77
4.32
3.56
3.02
2.72
13.61
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-1.47
-2.52
-1.54
-1.15
-1.29
-6.51
EBIT per share
-3.51
—
—
—
—
—
EBITDA per share
-3.51
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
8.2
3.98
2.84
1.89
2.01
10.72
Net current asset value per share
8.29
4.31
3.04
2
2.17
11.52
Tangible book value per share
6.1
3.31
2.19
1.34
1.37
8.22
Working capital per share
6.09
3.31
2.19
1.33
1.37
8.2
Book value per share
6.1
3.31
2.19
1.34
1.37
8.22
Notícias
Cadrenal registra prejuízo no 4º trimestre e conclui reunião com FDA sobre terapia para HIT
Cadrenal schedules FDA meeting for HIT drug CAD-1005
Ações da Cadrenal Therapeutics disparam com resultados de ensaio de Fase 2
Cadrenal Therapeutics stock surges on Phase 2 trial results
CAD-1005 da Cadrenal reduz coágulos sanguíneos em estudo sobre TIH
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial
Cadrenal destaca potencial de inibidor 12-LOX para distúrbio sanguíneo
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc.